The first 2 authors contributed equally to this work.
1097-0215/asset/olbannerleft.jpg?v=1&s=45719cd7de57873027993264fcc568b335a8cd56)
1097-0215/asset/olbannerright.jpg?v=1&s=5e0fba63c1309b3036eb9215a0e1e83dd02efd19)
Tumor Immunology
You have full text access to this OnlineOpen article
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro
Article first published online: 15 FEB 2006
DOI: 10.1002/ijc.21775
Copyright © 2006 Wiley-Liss, Inc.
Additional Information
How to Cite
Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., Gajewski, T. F., Theobald, M., Andreesen, R. and Mackensen, A. (2006), Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer, 119: 317–327. doi: 10.1002/ijc.21775
- ‡
The first 2 authors contributed equally to this work.
Publication History
- Issue published online: 27 APR 2006
- Article first published online: 15 FEB 2006
- Manuscript Accepted: 28 NOV 2005
- Manuscript Received: 4 AUG 2005
Funded by
- Deutsche Krebshilfe e.V.. Grant Number: 10-2204-Bl 1
- Deutsche Forschungsgemeinschaft. Grant Number: SFB 432 A3
- José Carreras Leukemia Foundation. Grant Number: DJCLS-H02/01/
- MAIFOR program
- Deutsche Krebshilfe e.V. (Tumor Vaccination Center)
Cited in:
- CrossRef
This article has been cited by:
- 1, , , B7-H1 Expression Model for Immune Evasion in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma, Head and Neck Pathology, 2013, 7, 2, 113
- 2, , Dendritic cell immunotherapy, Annals of the New York Academy of Sciences, 2013, 1284, 1Direct Link:
- 3, , , , , , , , , Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation, Endocrine Related Cancer, 2013, 20, 1, 103
- 4, , Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches, Expert Opinion on Biological Therapy, 2013, 13, 6, 911
- 5, , Strategies to reverse melanoma-induced T-cell dysfunction, Clinics in Dermatology, 2013, 31, 3, 251
- 6, , , , , T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment, Current Opinion in Immunology, 2013, 25, 2, 214
- 7, , , , , , , , , , , , , , Tumor-Specific T Cells in Human Merkel Cell Carcinomas: A Possible Role for Tregs and T-Cell Exhaustion in Reducing T-Cell Responses, Journal of Investigative Dermatology, 2013,
- 8, Advances in the Treatment of Metastatic Melanoma: New Immunomodulatory Agents, Seminars in Oncology, 2012, 39, 2, 192
- 9, , , , , , , , Costimulatory molecule expression on human uveal melanoma cells: Functional analysis of CD40 and B7-H1, Experimental Eye Research, 2012, 96, 1, 98
- 10, , , , , , , , , , , Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors, Cancer Gene Therapy, 2012, 19, 9, 637
- 11, , , , , Immunological Heterogeneity of the RCC Microenvironment: Do Targeted Therapies Influence Immune Response?, Current Oncology Reports, 2012, 14, 3, 230
- 12, , , Individualisierte Tumortherapie und Status quo beim Melanom, Onkologie, 2012, 35, s2, 2
- 13, , , , , , Lack of an association of programmed cell death-1 PD1.3 polymorphism with risk of hepatocellular carcinoma susceptibility in Turkish population: A case–control study, Gene, 2012, 511, 2, 308
- 14, , , , , , , , , , , , PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease, International Journal of Cancer, 2012, 130, 10Direct Link:
- 15, , , , Positive and Negative Regulation of Cellular Immune Responses in Physiologic Conditions and Diseases, Clinical and Developmental Immunology, 2012, 2012, 1
- 16, , Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when, Expert Review of Anticancer Therapy, 2012, 12, 6, 787
- 17, , , , , Targeting BRAFV600E in an Inducible Murine Model of Melanoma, The American Journal of Pathology, 2012, 181, 3, 785
- 18, Tim-3, a negative regulator of anti-tumor immunity, Current Opinion in Immunology, 2012, 24, 2, 213
- 19, , , , , , , , Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors, Cellular Immunology, 2012, 278, 1-2, 76
- 20, , Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach, Acta Haematologica Polonica, 2012, 43, 2, 132
- 21, , Animal Models of MS Reveal Multiple Roles of Microglia in Disease Pathogenesis, Neurology Research International, 2011, 2011, 1
- 22Cancer immunotherapy: Progress and challenges in the clinical setting, European Journal of Immunology, 2011, 41, 6Direct Link:
- 23, , , , , , , , Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett Carcinoma, The Annals of Thoracic Surgery, 2011, 91, 4, 1025
- 24, , , , , Emerging Tim-3 functions in antimicrobial and tumor immunity, Trends in Immunology, 2011, 32, 8, 345
- 25, , , , Follicular programmed death 1–positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma, Human Pathology, 2011, 42, 4, 552
- 26, , , , , High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Medical Oncology, 2011, 28, 3, 682
- 27, , Immunotherapy for Renal Cell Carcinoma, Hematology/Oncology Clinics of North America, 2011, 25, 4, 793
- 28, , , , , , Overall survival and PD-L1 expression in metastasized malignant melanoma, Cancer, 2011, 117, 10Direct Link:
- 29, , , , , , , , , PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China, Breast Cancer Research and Treatment, 2011, 129, 1, 195
- 30, , , , , , , , , , , , , , , , , Progressive Upregulation of PD-1 in Primary and Metastatic Melanomas Associated with Blunted TCR Signaling in Infiltrating T Lymphocytes, Journal of Investigative Dermatology, 2011, 131, 6, 1300
- 31, , , , , Therapeutic targeting of B7-H1 in breast cancer, Expert Opinion on Therapeutic Targets, 2011, 15, 10, 1211
- 32, , , , , , Clinical Significance of B7-H1 and B7-1 Expressions in Pancreatic Carcinoma, World Journal of Surgery, 2010, 34, 5, 1059
- 33, , Directing dendritic cell immunotherapy towards successful cancer treatment, Immunotherapy, 2010, 2, 1, 37
- 34, , , , , , , Immunotherapy for Melanoma: Current Status and Perspectives, Journal of Immunotherapy, 2010, 33, 6, 570
- 35, Immunotherapy for Prostate Cancer: An Emerging Treatment Modality, Urologic Clinics of North America, 2010, 37, 1, 121
- 36, , , , , , , , RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells, Cancer Immunology, Immunotherapy, 2010, 59, 8, 1173
- 37, , , , , , , siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells, Blood, 2010, 116, 22, 4501
- 38, , , , , , Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, Journal of Experimental Medicine, 2010, 207, 10, 2187
- 39, , , , , , , The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade, Gynecologic Oncology, 2010, 116, 2, 222
- 40, , , , , , , , Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma, Cancer, 2010, 116, 7Direct Link:
- 41, , , Costimulatory and coinhibitory receptors in anti-tumor immunity, Immunological Reviews, 2009, 229, 1Direct Link:
- 42, , , , , Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance, Journal of Huazhong University of Science and Technology [Medical Sciences], 2009, 29, 1, 77
- 43
- 44, , Immunotherapy: from basic research to clinical applications, Cancer Immunology, Immunotherapy, 2009, 58, 7, 1129
- 45, , , , , , , , , Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain, Journal of Experimental Medicine, 2009, 206, 2, 463
- 46, , , , , , , , , , , , PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients, Leukemia, 2009, 23, 2, 375
- 47, , , , , , , Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 2009, 114, 8, 1537
- 48, , , , , B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer, Clinical Immunology, 2008, 129, 3, 471
- 49, , , , , , , , , Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer, Cancer Letters, 2008, 268, 1, 98
- 50, , , , , , , Dendritic cell vaccines in melanoma: From promise to proof?, Critical Reviews in Oncology/Hematology, 2008, 66, 2, 118
- 51, , , , , , Effect of intrauterine HIV-1 exposure on the frequency and function of uninfected newborns’ dendritic cells, Clinical Immunology, 2008, 126, 3, 243
- 52, Immune escape as a fundamental trait of cancer: focus on IDO, Oncogene, 2008, 27, 28, 3889
- 53, , , , , , Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200, Cancer Immunology, Immunotherapy, 2008, 57, 7, 987
- 54, , , , , , , , , , , Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients, Journal of Immunotherapy, 2008, 31, 8, 781
- 55
- 56, , , , Immunogenic anti-cancer chemotherapy as an emerging concept, Current Opinion in Immunology, 2008, 20, 5, 545
- 57, , Inhibitory B7-family molecules in the tumour microenvironment, Nature Reviews Immunology, 2008, 8, 6, 467
- 58, , , , The complex role of B7 molecules in tumor immunology, Trends in Molecular Medicine, 2008, 14, 12, 550
- 59, , , , , , , , , , , , , , , The Programmed Death (PD)-1/PD-Ligand 1 Pathway Regulates Graft-Versus-Host-Reactive CD8 T Cells After Liver Transplantation, American Journal of Transplantation, 2008, 8, 11Direct Link:
- 60
- 61, , An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells, Cellular Immunology, 2007, 247, 2, 95
- 62, Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer, Nature Reviews Cancer, 2007, 7, 9, 701
- 63, , Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion, Cancer Immunology, Immunotherapy, 2007, 56, 5, 739
- 64, , , , , , Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment, Cancer Immunology, Immunotherapy, 2007, 56, 11, 1687
- 65, , From T-cell activation signals to signaling control of anti-cancer immunity, Immunological Reviews, 2007, 220, 1Direct Link:
- 66, , , , , , , , , , , , , Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma, Nature Medicine, 2007, 13, 1, 84
- 67, , , , , Melanocyte Receptors: Clinical Implications and Therapeutic Relevance, Dermatologic Clinics, 2007, 25, 4, 541
- 68, , , , , , , , , Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections, Current Opinion in HIV and AIDS, 2007, 2, 3, 219
- 69, , , Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), Cancer, 2007, 110, 12Direct Link:
- 70, , The New B7s: Playing a Pivotal Role in Tumor Immunity, Journal of Immunotherapy, 2007, 30, 3, 251
- 71, , The road to recovery: translating PD-1 biology into clinical benefit, Trends in Immunology, 2007, 28, 2, 48
- 72
- 73, Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?, Expert Review of Vaccines, 2006, 5, 6, 773